GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Voclosporin capsules (Lupkynis)

Read renal action and limits
Local official-label summarySource retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons

Lupkynis / Voclosporin

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Lupkynis - product and source limitations

Check the label's lower starting regimen if used in severe impairment and its eGFR monitoring and adjustment algorithm.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Lupkynis - product and source limitations

Rxlist source

Lupkynis - selected RX renal passage

Choose a product and source Lupkynis | Product label All evidence
Product / population
Voclosporin (Lupkynis), oral capsule
Renal measure
Use the renal measure explicitly present in the RX passage.
Source revision
Mirror revision not established in the reviewed passage.
Retrieved
2026-11-07 (not the revision date)

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

This mirror and the underlying product label share a source family.

RX List: selected renal passage

If baseline eGFR is 45 mL/min/1.73 m2 or lower, voclosporin is not recommended unless the expected benefit outweighs the risk.

Source revision: Mirror revision not established in the reviewed passage. | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/lupkynis-drug/

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Lupkynis - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 12, posted Aug 27, 2026

Renal measure: Indexed GFR/eGFR, mL/min/1.73 m2

Read this dated source finding
Rxlist

Lupkynis - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding
See all retained evidence sources
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

Lupkynis - selected RX renal passage

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Voclosporin (Lupkynis), oral capsule

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Lupkynis - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Lupkynis - product and source limitations

Check the label's lower starting regimen if used in severe impairment and its eGFR monitoring and adjustment algorithm.

How to use this: Apply only to the stated formulation, indication and renal population.

Lupkynis - labeled renal guidanceLupkynis - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeVoclosporin capsules (Lupkynis) - selected U.S. label sectionsLupkynis - labeled renal guidanceLupkynis - selected RX renal passage
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f489295-1156-52c7-5fd0-5c4c52f9b813

Product and population scope

Adult LUPKYNIS oral capsules for active lupus nephritis with the labeled background therapy.

RDM32-voclosporin-lupkynis-scope · Source section: Editorial scope for the selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Voclosporin capsules (Lupkynis) - selected U.S. label sections

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adult LUPKYNIS oral capsules for active lupus nephritis with the labeled background therapy.

Renal method: eGFR in mL/min/1.73 m2, including percentage change from baseline
Source date: 10/2025
Retrieved: 2026-09-05

Local label summary; independent clinical review pending. Not a two-source validated protocol.

Baseline renal eligibility

Baseline eGFR at or below 45: generally not recommended unless benefit exceeds risk; this population was not studied. If treatment is chosen despite severe impairment, the reduced starting dose is 15.8 mg twice daily.

RDM32-voclosporin-lupkynis-1 · Source locator: 2.4; 8.6

On-treatment renal algorithm

Monitor eGFR every 2 weeks in month 1, every 4 weeks through year 1, then quarterly.

If eGFR is below 60 and falls more than 20% but less than 30% from baseline, reduce each twice-daily dose by 7.9 mg. Recheck within 2 weeks; if the fall remains above 20%, reduce again by 7.9 mg twice daily.

If eGFR is below 60 and the fall is at least 30%, discontinue. Recheck within 2 weeks; consider restarting 7.9 mg twice daily only after recovery to at least 80% of baseline. After a renal-driven reduction, consider increasing by 7.9 mg twice daily for each measurement at least 80% of baseline, without exceeding the starting dose.

RDM32-voclosporin-lupkynis-2 · Source locator: 2.3

Source-specific limits

Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.

Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f489295-1156-52c7-5fd0-5c4c52f9b813
Retrieved
2026-09-05
DailyMed Set ID
9f489295-1156-52c7-5fd0-5c4c52f9b813
Label revision
10/2025
Renal-function method
eGFR in mL/min/1.73 m2, including percentage change from baseline
Source date/version
10/2025
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or a label PDF.
Local summary SHA-256
1bc2cd50789455930cd0000a73a5570f975e0cdaa4a906f183292a55afad869d
Official

Lupkynis - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Voclosporin (Lupkynis), oral capsule

Renal method: Indexed GFR/eGFR, mL/min/1.73 m2
Source date: DailyMed SPL version 12, posted Aug 27, 2026
Retrieved: 2026-11-07

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 8.6 Renal Impairment / 2.4 Dosage Recommendations in Patients with Renal and Hepatic Impairment

If baseline eGFR is 45 mL/min/1.73 m2 or lower, voclosporin is not recommended unless the expected benefit outweighs the risk. Check the label's lower starting regimen if used in severe impairment and its eGFR monitoring and adjustment algorithm.

RDM74-lupkynis-official-1 · Source locator: Renal guidance: 8.6 Renal Impairment / 2.4 Dosage Recommendations in Patients with Renal and Hepatic Impairment

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f489295-1156-52c7-5fd0-5c4c52f9b813
Retrieved
2026-11-07
Renal-function method
Indexed GFR/eGFR, mL/min/1.73 m2
Source date/version
DailyMed SPL version 12, posted Aug 27, 2026
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
09082103a7f931c882fd74d650c88ef279f6004ec9a0530df64eedb756530885
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Lupkynis - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Voclosporin (Lupkynis), oral capsule

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

If baseline eGFR is 45 mL/min/1.73 m2 or lower, voclosporin is not recommended unless the expected benefit outweighs the risk.

RDM74-lupkynis-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/lupkynis-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
11365e96d00636af6119ab20141533ef1dc732c84b22ea8e8ad9454b6b11c95d

Provenance and preservation

Additional summaries stored on this page: 2 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f489295-1156-52c7-5fd0-5c4c52f9b813
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
2b7ba0102dc1989c18141e105f05e80c3ce822ccd1698042f47c790b8afc26fb
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top